Search Within

Jennifer Kimberly Lue

Formats
  1. Meeting Abstract (36)
  2. Journal Article (8)
  3. Book Section (2)
  4. Research Letter (2)
  5. Review (1)
Groups
  1. Department of Medicine (42)
  2. Hematologic Malignancies, Division of (42)
  3. Center for Hematologic Malignancies (40)
  4. Lymphoma (40)
  5. Hematology-Oncology Fellows (35)
  6. GSK Faculty (32)

More Groups

People
  1. Gilles Salles (41)
  2. Lorenzo Falchi (39)
  3. Andrew Zelenetz (36)
  4. Anita Kumar (36)
  5. Maria Palomba (36)
  6. Paul Hamlin (32)

More People

Years
  1. 2025 (3)
  2. 2024 (22)
  3. 2023 (19)
  4. 2022 (5)
Publications
  1. Blood (33)
  2. Hematological Oncology (3)
  3. Blood Advances (2)
  4. Haematologica (2)
  5. Journal of Clinical Oncology (2)
  6. Leukemia and Lymphoma (2)

More Publications

Publishers
  1. American Society of Hematology (35)
  2. Wiley Blackwell (5)
  3. American Society of Clinical Oncology (2)
  4. Ferrata Storti Foundation (2)
  5. Taylor & Francis Group (2)
  6. Elsevier Inc. (1)

More Publishers

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
    Research Letter

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Pak, T.; Chang, T.; Dao, P.; Moskowitz, A. J.; Stuver, R. N.; Ghione, P.; Galasso, N.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study
    Meeting Abstract

    Lue, J. K.; Morschhauser, F.; Tilly, H.; Lenz, G.; Jardin, F.; Herrera, A. F.; Sharman, J. P.; Flowers, C.; Friedberg, J. W.; Trneny, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma
    Journal Article

    Ryu Tiger, Y. K.; Jain, S.; Barta, S. K.; Tolu, S.; Estrella, B.; Sawas, A.; Lue, J. K.; Francescone, M. M.; Pro, B.; Amengual, J. E.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Pharmacology to practice: The similarities and differences of drugs targeting CD20
    Book Section

    Lue, J. K.; Cheson, B. D.
    In O'Connor, O. A.; Ansell, S. M.; Gribben, J. G. (Eds.) Precision Cancer Therapies: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice (2024)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save